Hydroxychloroquine Prophylaxis in COVID-19 – Debunking the Myth
Dr Swapnil Pawar
The only strategies that worked so far in COVID-19 to mitigate transmission are rapid identification of cases, isolation, contact tracing, and self-quarantine of those exposed. To date, no medication has been shown to prevent SARS-CoV-2 transmission.
This trial hypothesized that hydroxychloroquine could potentially be used as postexposure prophylaxis, to prevent symptomatic infection after exposure to Covid-19.
The study was conducted in Canada and the US.
Multicentre Randomised controlled trial.
Inclusion Criteria –
Exclusion Criteria :
Participants were self-enrolled through a secure Internet-based survey using the REDCAP system. Follow-up by email survey on days 1, 5, 10, and 14. A later survey was carried out 4–6 weeks to assess illness, hospitalization, and follow-up testing. The study subject was contacted first; if this was not possible, the emergency contact was contacted for follow-up information.
Intervention: The initial dose of hydroxychloroquine:
800 mg (4 tablets) once
600 mg (3 tablets) 6 to 8 hours later
600 mg (3 tablets) daily for 4 more days for a total course of 5 days. This dose was calculated based on the in vitro half-maximal effective concentration of HCQ against SARS-CoV-2 (the plasma concentration was targeted to be above this level).
Control: Placebo folate tablets, which were similar in appearance to the hydroxychloroquine tablets, prescribed as an identical regimen.
A 10% possibility of acquiring infection was assumed. The sample size was calculated based on a 50% relative effect size to reduce new symptomatic infections. For a two-sided alpha of 0.05, and 90% power, 621 persons were required in each group. Allowing for 20% attrition, 750 were planned to be included in each group.
The study was stopped for futility at the 3rd interim analysis after enrollment of 821 patients (HCQ: 414 participants vs. placebo: 407 participants).
Overall, Overall, new Covid-19 infection (either PCR-confirmed or symptomatically compatible) occurred in 107 of 821 participants (13.0%) during the 14 days of follow-up. Of all study subjects, 66.4% were HCWs (545 of 821). This included physicians or physician assistants (62.8%) and nurses or nursing assistants (23.5%).
symptomatic illness confirmed by a positive molecular assay or, if testing was unavailable,
Covid-19– related symptoms – included probable cases (presence of cough, shortness of breath, or difficulty breathing, or the presence of two or more symptoms of fever, chills, rigors, myalgia, headache, sore throat, and new olfactory and taste disorders), and possible cases (the presence of one or more compatible symptoms, which could include diarrhea)
Access to testing was limited. Four ID physicians arbitrated on whether the subjects met the criteria for COVID-19 diagnosis.
46 subjects in the hydroxychloroquine group and 42 in the placebo group did not complete the day 14 survey.
The vital status was unknown for 36 in the hydroxychloroquine group and 33 in the control group.
No difference in sensitivity analysis either including or excluding them from the final analysis.
The primary outcome occurred in 49 of 414(11.8%) patients in the HCQ groups vs. 58 of 407 (14.3%) in the placebo group (P=0.35).
2. Death: No death occurred in either group
113 subjects developed symptomatic illness; 4 remained asymptomatic during the 14-day follow-up period.
Of the 113 subjects who developed symptomatic illness:
16 subjects had PCR-confirmed disease. (4 were asymptomatic positive; out of this, 3 developed symptoms after the 14-d follow-up period)
74 subjects developed probable illness (Covid-19 according to the U.S. case definition)
13 subjects experienced possible illness (compatible symptoms and epidemiologic linkage)
10: adjudicated as not having Covid-19
Adherence: 75.4% of participants with hydroxychloroquine group (312 of 414) and 82.6% with the placebo group (336 of 407) (P=0.01) adhered to the protocol
Adverse events were observed in 17 participants in the hydroxychloroquine group vs. 8 in the placebo group. Nausea, loose stools, and abdominal discomfort were the most common side effects.
There were no serious intervention-related adverse reactions or cardiac arrhythmias.
Welcome trial as it tried to address the right question.
Limitations of the trial make it difficult to draw any conclusions just based on this trial. This trial is considered more provocative than definitive.
However, most of the countries have already stopped using HCQ for Post-exposure prophylaxis.
Dr Swapnil Pawar July 2, 2020
RECOVERY TRIAL The RECOVERY trial is a randomized clinical trial designed to evaluate several treatment modalities in patients with COVID-19 infection. 11,000 patients from 175 hospitals of the National Health […]